Altre lingue Intensity Therapeutics, Inc.

Azioni

INTS

US45828J1034

Tempo differito Nasdaq Altri mercati azionari 18:52:16 24/06/2024			Variaz. 5gg	Var. 1 gen.
4,85 ^USD	0,00%		+3,41%	-43,41%

15/05	Intensity Therapeutics, Inc. nomina Thomas Dubin nel Consiglio di Amministrazione	CI
10/05	Intensity Therapeutics, Inc. stipula un accordo di collaborazione con il Gruppo svizzero per la ricerca sul cancro SAKK	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors	15/05
Intensity Therapeutics, Inc. Appoints Thomas Dubin to the Board of Directors	15/05
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe	13/05
Intensity Therapeutics, Inc. Enters into A Collaboration Agreement with the Swiss Group for Cancer Research SAKK	10/05
Intensity Therapeutics Collaborates With Swiss Group on Clinical Research for Breast Cancer Trial	10/05
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate	10/05
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate	10/05
Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update	09/05
Intensity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Intensity Therapeutics : Failure to Satisfy Listing Rule - Form 8-K	19/04
Intensity Therapeutics, Inc. Announces Resignation of Daniel Donovan from Audit Committee of the Board of Directors	19/04
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024	02/04
Portage biotech completes monetization of intensity therapeutics shares	27/03
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares	26/03
Intensity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024	14/03
Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference	21/02
Intensity Therapeutics Gets FDA Green Light for Phase 3 Study	03/01
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program	03/01
Certain Common Stock of Intensity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 26-DEC-2023.	26/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Intensity Therapeutics, Inc.

Azioni

INTS

US45828J1034

Altre lingue

Filtri